AURX

Nuo Therapeutics, Inc.

Price Chart

Latest Quote

$1.06

-0.01 (-0.93%)

Current Price

Previous Close	$1.07
Open	$1.06
Day High	$1.06
Day Low	$1.06
Volume	145

Fetched: 2026-06-04T18:17:29

Stock Information

Shares Outstanding	48.41M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$51.31M
EPS (TTM)	$-0.04
Exchange	OQB

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Book/sh	$-0.02
Employees	10

Financial Ratios

Returns & Margins

Ownership

Insider Ownership	57.93%
Institutional Ownership	2.13%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-106.00
P/B	-53.00

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$1.15
SMA50	$1.31
SMA200	$1.77
RSI	39.49
ATR	0.0963

Rel Volume

0.18

Performance History

Week	+7.07%
Month	-11.67%
Quarter	-24.29%
6 Months	-53.10%
YTD	-47.00%
Year	-27.89%
3 Years	-32.16%
5 Years	+41.33%
10 Years	+1225.00%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-03	$1.06	650
2026-06-02	$1.07	2,700
2026-06-01	$1.02	1,500
2026-05-29	$0.99	100
2026-05-28	$1.03	300
2026-05-27	$0.99	1,360
2026-05-26	$0.99	2,500
2026-05-22	$1.11	2,360
2026-05-21	$1.01	7,160
2026-05-20	$1.15	1,002
2026-05-19	$1.11	100
2026-05-18	$1.35	0
2026-05-15	$1.35	0
2026-05-14	$1.35	12,800
2026-05-13	$1.25	0
2026-05-12	$1.25	10,200
2026-05-11	$1.16	3,300
2026-05-08	$1.26	7,790
2026-05-07	$1.28	13,599
2026-05-06	$1.20	5,792
2026-05-05	$1.20	2,509
2026-05-04	$1.20	1,700

About Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.

📰 Latest News

No news articles available at the moment. Check back later for updates on AURX.

Period:

Income Statement (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue
Reconciled Cost Of Revenue	$302,842	$126,092	$19,214	$0
Cost Of Revenue	$302,842	$126,092	$19,214	$0
Total Revenue	$1,365,173	$608,525	$112,250	$0
Operating Revenue	$1,365,173	$608,525	$112,250	$0
Expenses
Total Expenses	$3,823,008	$3,776,799	$3,432,844	$90,670
Other Income Expense	$134,025	-	$150,961	-
Other Non Operating Income Expenses	$134,025	-	$4,523	-
Net Non Operating Interest Income Expense	$105	$-3,162	$-2,103	$0
Total Other Finance Cost	$-105	$3,162	-	-
Operating Expense	$3,520,166	$3,650,707	$3,413,630	$90,670
Interest Expense	-	$3,162	$2,103	$0
Interest Expense Non Operating	-	$3,162	$2,103	$0
Selling And Marketing Expense	-	-	-	$0
General And Administrative Expense	-	-	-	$90,670
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-2,323,705	$-3,171,436	$-3,171,736	$-90,670
Net Interest Income	$105	$-3,162	$-2,103	$0
Normalized Income	$-2,323,705	$-3,171,436	$-3,318,174	$-90,670
Net Income From Continuing And Discontinued Operation	$-2,323,705	$-3,171,436	$-3,171,736	$-90,670
Total Operating Income As Reported	$-2,457,835	$-3,168,274	$-3,320,594	$-90,670
Net Income Common Stockholders	$-2,323,705	$-3,171,436	$-3,171,736	$-886,262
Net Income	$-2,323,705	$-3,171,436	$-3,171,736	$-90,670
Net Income Including Noncontrolling Interests	$-2,323,705	$-3,171,436	$-3,171,736	$-90,670
Net Income Continuous Operations	$-2,323,705	$-3,171,436	$-3,171,736	$-90,670
Pretax Income	$-2,323,705	$-3,171,436	$-3,171,736	$-90,670
Operating Income	$-2,457,835	$-3,168,274	$-3,320,594	$-90,670
Gross Profit	$1,062,331	$482,433	$93,036	$0
Special Income Charges	-	$0	$146,438	$0
Per Share
Diluted EPS	$-0.05	$-0.08	$-0.08	$-0.03
Basic EPS	$-0.05	$-0.08	$-0.08	$-0.03
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-2,361,566	$-3,063,016	$-3,241,989	$-90,670
Reconciled Depreciation	$96,269	$105,258	$74,082	$0
EBITDA (Bullshit earnings)	$-2,361,566	$-3,063,016	$-3,095,551	$-90,670
EBIT	$-2,457,835	$-3,168,274	$-3,169,633	$-90,670
Diluted Average Shares	$45,424,437	$42,077,811	$40,001,089	$30,296,376
Basic Average Shares	$45,424,437	$42,077,811	$40,001,089	$30,296,376
Diluted NI Availto Com Stockholders	$-2,323,705	$-3,171,436	$-3,171,736	$-886,262
Selling General And Administration	$3,520,166	$3,650,707	$3,413,630	$90,670
Total Unusual Items	-	$0	$146,438	$0
Total Unusual Items Excluding Goodwill	-	$0	$146,438	$0
Otherunder Preferred Stock Dividend	-	-	$0	$795,592
Other Special Charges	-	-	$-146,438	-
Tax Provision	-	-	-	$0
Research And Development	-	-	-	$0
Other Gand A	-	-	-	$90,670

Fetched: 2026-02-02

Balance Sheet (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Net Tangible Assets	$513,712	$1,039,148	$2,191,338	$792,839
Total Assets	$1,189,508	$1,877,880	$3,047,360	$1,465,918
Total Non Current Assets	$347,962	$314,436	$412,449	$0
Current Assets	$841,546	$1,563,444	$2,634,911	$1,465,918
Other Current Assets	$159,185	$174,471	$196,378	$51,349
Inventory	$150,442	$209,589	$240,005	$0
Receivables	$248,205	$250,703	$92,320	$0
Accounts Receivable	$248,205	$250,703	$92,320	$0
Allowance For Doubtful Accounts Receivable	$-25,000	$-32,400	-	-
Gross Accounts Receivable	$273,205	$283,103	-	-
Cash Cash Equivalents And Short Term Investments	$283,714	$928,681	$2,051,208	$1,414,569
Cash And Cash Equivalents	$283,714	$928,681	$2,051,208	$1,414,569
Cash Financial	$283,714	$928,681	-	-
Restricted Cash	-	$0	$55,000	$0
Prepaid Assets	-	-	-	$1,500
Debt
Total Debt	$164,206	$255,592	$335,045	$0
Long Term Debt And Capital Lease Obligation	$97,345	$164,205	$255,592	$0
Current Debt And Capital Lease Obligation	$66,861	$91,387	$79,453	-
Liabilities
Total Liabilities Net Minority Interest	$675,796	$838,732	$856,022	$673,079
Total Non Current Liabilities Net Minority Interest	$97,345	$164,205	$255,591	$0
Current Liabilities	$578,451	$674,527	$600,431	$673,079
Payables And Accrued Expenses	$511,590	$583,140	$520,978	$673,079
Payables	$471,590	$563,740	$520,978	$663,079
Other Payable	$252,400	$169,222	$123,275	$136,522
Accounts Payable	$219,190	$394,518	$397,703	$526,557
Other Non Current Liabilities	-	-	$-1	-
Equity
Common Stock Equity	$513,712	$1,039,148	$2,191,338	$792,839
Total Equity Gross Minority Interest	$513,712	$1,039,148	$2,191,338	$792,839
Stockholders Equity	$513,712	$1,039,148	$2,191,338	$792,839
Retained Earnings	$-32,259,946	$-29,936,241	$-26,764,805	$-23,593,069
Other
Ordinary Shares Number	$46,816,114	$44,241,516	$41,799,016	$37,124,205
Share Issued	$46,816,114	$44,241,516	$41,799,016	$37,124,205
Tangible Book Value	$513,712	$1,039,148	$2,191,338	$792,839
Invested Capital	$513,712	$1,039,148	$2,191,338	$792,839
Working Capital	$263,095	$888,917	$2,034,480	$792,839
Capital Lease Obligations	$164,206	$255,592	$335,045	$0
Total Capitalization	$513,712	$1,039,148	$2,191,338	$792,839
Additional Paid In Capital	$32,768,976	$30,970,965	$28,951,963	$24,382,195
Capital Stock	$4,682	$4,424	$4,180	$3,713
Common Stock	$4,682	$4,424	$4,180	$3,713
Long Term Capital Lease Obligation	$97,345	$164,205	$255,592	$0
Current Capital Lease Obligation	$66,861	$91,387	$79,453	$0
Current Accrued Expenses	$40,000	$19,400	$0	$10,000
Net PPE	$347,962	$314,436	$412,449	$0
Accumulated Depreciation	$-432,841	$-409,819	$-394,492	$-387,665
Gross PPE	$780,803	$724,255	$806,941	$387,665
Other Properties	$732,784	$680,336	$766,915	$387,665
Machinery Furniture Equipment	$48,019	$43,919	$40,026	$0

Fetched: 2026-02-02

Cash Flow Statement (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Free Cash Flow
Free Cash Flow	$-2,386,584	$-3,175,026	$-3,766,118	$-119,955
Operating Activities
Operating Cash Flow	$-2,231,622	$-3,167,782	$-3,706,126	$-119,955
Cash Flow From Continuing Operating Activities	$-2,231,622	$-3,167,781	$-3,706,125	$-119,955
Investing Activities
Capital Expenditure	$-154,962	$-7,244	$-59,992	-
Investing Cash Flow	$-154,962	$-7,244	$-59,992	$0
Cash Flow From Continuing Investing Activities	$-154,962	$-7,244	$-59,992	$0
Financing Activities
Issuance Of Capital Stock	$1,500,000	$1,997,500	$4,457,757	$0
Financing Cash Flow	$1,741,617	$1,997,500	$4,457,757	$1,373,092
Cash Flow From Continuing Financing Activities	$1,741,617	$1,997,500	$4,457,757	$1,373,092
Net Common Stock Issuance	$1,500,000	$1,997,500	$4,457,757	$0
Common Stock Issuance	$1,500,000	$1,997,500	$4,457,757	$0
Other
Interest Paid Supplemental Data	$4,494	$4,003	$2,268	$0
End Cash Position	$283,714	$928,681	$2,106,208	$1,414,569
Beginning Cash Position	$928,681	$2,106,208	$1,414,569	$161,432
Changes In Cash	$-644,967	$-1,177,527	$691,639	$1,253,137
Proceeds From Stock Option Exercised	$241,617	$0	$0	$1,373,092
Net PPE Purchase And Sale	$-154,962	$-7,244	$-59,992	$0
Purchase Of PPE	$-154,962	$-7,244	$-59,992	$0
Change In Working Capital	$-36,660	$-299,423	$-471,178	$-43,221
Change In Other Current Liabilities	$-66,218	$-79,452	$-91,494	$0
Change In Payables And Accrued Expense	$62,072	$62,162	$97,670	$8,128
Change In Accrued Expense	$103,778	$65,347	$80,086	$0
Change In Payable	$-41,706	$-3,185	$17,584	$8,128
Change In Account Payable	$-41,706	$-3,185	$17,584	$8,128
Change In Prepaid Assets	$15,286	$21,907	$-145,029	$-51,349
Change In Inventory	$29,147	$14,343	$-240,005	$0
Change In Receivables	$-76,947	$-318,383	$-92,320	$0
Changes In Account Receivables	$-76,947	$-318,383	$-92,320	$0
Other Non Cash Items	$-133,623	$-1	$-146,439	-
Stock Based Compensation	$56,652	$21,746	$9,145	$13,936
Provisionand Write Offof Assets	$109,445	$176,074	$0	-
Depreciation Amortization Depletion	$96,269	$105,258	$74,082	$0
Depreciation And Amortization	$96,269	$105,258	$74,082	$0
Depreciation	$96,269	$105,258	$74,082	$0
Net Income From Continuing Operations	$-2,323,705	$-3,171,436	$-3,171,736	$-90,670
Income Tax Paid Supplemental Data	-	$0	$0	$0
Asset Impairment Charge	-	$16,074	$0	-

Fetched: 2026-02-02